Gene therapy for hearing loss caused by otoferlin gene changes
Tests AAVAnc80-hOTOF gene therapy in people with otoferlin-related hearing loss.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- London, United KingdomSee the siteAlso in 3 other countries, 8 sites
- Trial code
- Registry title
- Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 48 people, planned
- Started
- 15 Sept 2023
- Expected to end
- Dec 2029
- Type of study
- Interventional, 6 groups
- Treatments tested
- AAVAnc80-hOTOF via Akouos Delivery Device
- AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
- Record updated
- 29 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people of any age with hearing loss in both ears caused by changes in the otoferlin gene. They get a one-time gene therapy, AAVAnc80-hOTOF, placed in one or both ears.
- Age
- Any age, depending on the study group. Some early groups needed people aged 7 to 17 years or at least two years old.
- Sex
- All sexes can join.
- Disease stage
- Profound (Part A) or severe to profound (Parts B, C and D) sensorineural hearing loss in both ears, measured by ABR (a brain response hearing test).
- Earlier treatment
- No cochlear implant in the ear that gets the gene therapy. No investigational drug in a trial in the 6 months before treatment. No earlier gene therapy trial, except AK-OTOF-101 for Part D. Part D is for people already treated in one ear in this trial.
- Biomarker or test result
- At least two mutations in the otoferlin gene. Preserved distortion product otoacoustic emissions (DPOAEs), a test showing the inner ear's hair cells still respond to sound.
Main reasons for not taking part
- Ear infections that keep coming back
- Abnormal ear structure or other ear problems
- Health problems that rule out surgery, anesthesia or gene therapy
- Cochlear implant in the ear to be treated
- Investigational drug in the past 6 months or any earlier gene therapy trial (except AK-OTOF-101 for Part D)
The registry criteria, word for word
Show all 9 criteriaShow less
Other criteria
- Criteria for Inclusion:
- Participants may be of any age, based on Cohort Criteria
- At least two mutations in the otoferlin gene
- Clinical presentation of Profound (Part A) or Severe to Profound (Parts B, C, and D) bilateral sensorineural hearing loss as assessed by ABR
- Preserved distortion product otoacoustic emissions (DPOAEs)
- Able and willing to comply with all study requirements, including willingness to participate in a separate long term follow-up study after completion of this trial; Criteria for Exclusion:
- Persistent ear infections, anatomic or other abnormalities of the ear, and/or medical conditions that would contraindicate undergoing surgery, anesthesia, and/or administration of investigational gene therapy
- Cochlear Implant(s) in the ear(s) to receive AAVAnc80-hOTOF
- Prior participation in a clinical trial with an investigational drug, within six months prior to administration, or any prior participation in a gene therapy clinical trial (with the exception of AK-OTOF-101 for Part D participants)
Where in United Kingdom
Also in 3 other countries, 8 sites
- University College LondonLondon, United KingdomContact: Lilly Clinical TrialsNo longer taking part
About the trial
What the trial wants to find out
Part A of this trial evaluated the safety and tolerability of a single surgical administration procedure in one or both ear(s) with one of two dose levels of AAVAnc80-hOTOF (LY888891) and evaluated the Akouos Delivery Device, together with the Precision Delivery Mechanism (as applicable), to safely achieve the intended product performance.
Read full original descriptionShow less
Part B of the trial is an open-label, global expansion phase to confirm the efficacy and safety of one dose level of AAVAnc80-hOTOF administered in one or both ear(s). Part B will also evaluate the Intracochlear Delivery System (IDS), which consists of the Akouos Delivery Device, the Precision Delivery Mechanism, and an off-the-shelf syringe.
Part C is a region-specific expansion phase. Part C participants will receive the same dose level of AAVAnc80-hOTOF as participants in Part B, in one or both ear(s) utilizing the IDS.
Part D is a sequential administration phase that allows participants who received AAVAnc80-hOTOF previously in a single ear to receive AAVAnc80-hOTOF administration in the other ear utilizing the IDS.
The 6 groups in the trial
- Part A: Cohort 1a and Cohort 1bTreatment being tested
Cohort 1a: Two participants aged 7 to 17 years old (inclusive) to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device Cohort 1b: Up to six eligible participants will be enrolled to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device; the first three participants will be at least two years of age at the time of AAVAnc80-hOTOF administration and the next three participants may be of any age
Treatment: AAVAnc80-hOTOF via Akouos Delivery Device
- Part A: Cohort 2Treatment being tested
Cohort 2: Up to six eligible participants will be enrolled to receive intracochlear administration of AAVAnc80-hOTOF (dose level 2) in the study ear using a sterile, one-time use investigational medical device; the first three participants will be at least two years of age at the time of AAVAnc80-hOTOF administration and the next three participants may be of any age
Treatment: AAVAnc80-hOTOF via Akouos Delivery Device
- Part A: Bilateral ExpansionTreatment being tested
Bilateral Expansion: up to eight eligible participants of any age, and no cochlear implants, may be eligible for enrollment into the Bilateral Expansion Cohort (simultaneous bilateral administration of AAVAnc80-hOTOF).
Treatment: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
- Part BTreatment being tested
Part B: Sixteen participants of any age will be enrolled to receive a single unilateral or bilateral administration of AAVAnc80-hOTOF. Participants with one CI will receive unilateral administration of AAVAnc80-hOTOF, while participants with no CIs will have the choice to receive a unilateral or bilateral administration of AAVAnc80-hOTOF, provided both ears meet eligibility criteria.
Treatment: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
- Part CTreatment being tested
Up to ten eligible participants of any age will be enrolled in a region-specific expansion phase to receive a single unilateral or bilateral administration of AAVAnc80-hOTOF. Participants with one CI will receive unilateral administration of AAVAnc80-hOTOF, while participants with no CIs will have the choice to receive a unilateral or bilateral administration of AAVAnc80-hOTOF, provided both ears meet eligibility criteria.
Treatment: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
- Part DTreatment being tested
Participants of any age may be enrolled into Part D, which is a sequential administration phase that allows participants who received unilateral administration of AAVAnc80-hOTOF in AK-OTOF-101 (Parts A, B, or C) the option to receive dose administration of AAVAnc80-hOTOF in the contralateral ear after completing the Year 1 visit.
Treatment: AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Trial of AAVAnc80-hOTOF Gene Therapy in Individuals With Sensorineural Hearing Loss Due to Otoferlin Gene Mutations
- Plain-language title
- Gene therapy for hearing loss caused by otoferlin gene changesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 29 September 2026